Literature DB >> 1709423

Clinical features and management of distant metastases of nasopharyngeal carcinoma.

S F Leung1, P M Teo, W W Shiu, S Y Tsao, T W Leung.   

Abstract

This is a retrospective study of 90 patients who developed distant metastases after radical radiotherapy for nasopharyngeal carcinoma. The skeleton was the commonest site of distant metastases. Clubbing, hypercalcemia and malignant fever occurred in about 10% of patients with pulmonary, skeletal and hepatic metastases respectively. An effective chemotherapeutic regimen for palliation of pulmonary and hepatic metastases was cisplatinum/carboplatin-5FU which gave a complete response rate of 29% and partial response rate of 21%. This was considered superior to some non-cisplatinum-containing regimens. One patient with hepatic metastases had good palliation by hepatic irradiation. The median survival of all patients with distant metastases was eight months. Five (6%) patients survived more than two years with one surviving free of disease at 31 months. Hepatic metastases and spinal cord compression were associated with short survivals.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1709423

Source DB:  PubMed          Journal:  J Otolaryngol        ISSN: 0381-6605


  19 in total

1.  M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma.

Authors:  Lujun Shen; Jun Dong; Sheng Li; Yue Wang; Annan Dong; Wanhong Shu; Ming Wu; Changchuan Pan; Yunfei Xia; Peihong Wu
Journal:  Oncologist       Date:  2015-02-06

2.  EphA2 silencing in nasopharyngeal carcinoma leads to decreased proliferation, invasion and increased sensitization to paclitaxel.

Authors:  Pingqing Tan; Yong Liu; Changyun Yu; Zhongwu Su; Guo Li; Xiaojuan Zhou; Donghai Huang; Xin Zhang; Yuanzheng Qiu; Yongquan Tian
Journal:  Oncol Lett       Date:  2012-06-08       Impact factor: 2.967

3.  Inhibiting ERp29 expression enhances radiosensitivity in human nasopharyngeal carcinoma cell lines.

Authors:  Lin Qi; Ping Wu; Xin Zhang; Yuanzheng Qiu; Weihong Jiang; Donghai Huang; Yong Liu; Pingqing Tan; Yongquan Tian
Journal:  Med Oncol       Date:  2011-04-11       Impact factor: 3.064

4.  Identification of heat shock protein 27 as a radioresistance-related protein in nasopharyngeal carcinoma cells.

Authors:  Bin Zhang; Jia-Quan Qu; Liang Xiao; Hong Yi; Peng-Fei Zhang; Mao-Yu Li; Rong Hu; Xun-Xun Wan; Qiu-Yan He; Jian-Huang Li; Xu Ye; Zhi-Qiang Xiao; Xue-Ping Feng
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-31       Impact factor: 4.553

5.  Downregulation of Annexin A1 is correlated with radioresistance in nasopharyngeal carcinoma.

Authors:  Lifang Huang; Li Liao; Yanping Wan; Ailan Cheng; Meixiang Li; Sihan Chen; Maoyu Li; Xing Tan; Guqing Zeng
Journal:  Oncol Lett       Date:  2016-10-27       Impact factor: 2.967

6.  Subdividing the M1 stage of liver metastasis for nasopharyngeal carcinoma to better predict metastatic survival.

Authors:  Changchuan Pan; Ni He; Ming Zhao; Yangkui Gu; Zilin Huang; Wang Li; Yunfei Xia; Peihong Wu
Journal:  Med Oncol       Date:  2010-09-04       Impact factor: 3.064

7.  Outcome of surgical management of persistent or recurrent neck mass in patients with nasopharyngeal carcinoma after radiotherapy.

Authors:  Cheng-Yu Lin; Sen-Tien Tsai; Ying-Tai Jin; Ming-Wei Yang; I-Chun Yeh; Jenn-Ren Hsiao
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-12-07       Impact factor: 2.503

8.  Solitary rib metastasis of nasopharyngeal carcinoma.

Authors:  Francesca De Felice; Daniela Musio; Anna Lisa Magnante; Nadia Bulzonetti; Irene De Francesco; Vincenzo Tombolini
Journal:  Chin J Cancer Res       Date:  2014-04       Impact factor: 5.087

9.  Characterization of TRIP6-dependent nasopharyngeal cancer cell migration.

Authors:  Jie Fei; Jihong Li; Sunan Shen; Weidong Zhou
Journal:  Tumour Biol       Date:  2013-04-11

10.  Identification of ERp29 as a biomarker for predicting nasopharyngeal carcinoma response to radiotherapy.

Authors:  Ping Wu; Hua Zhang; Lin Qi; Qingping Tang; Yaoyun Tang; Zhihai Xie; Yunxia Lv; Suping Zhao; Weihong Jiang
Journal:  Oncol Rep       Date:  2011-12-08       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.